MESO
Fiscal year ends June Quarters are offset from the calendar — Q1 is Jul–Sep

Mesoblast Limited is a biotechnology company developing allogeneic cellular medicines for severe inflammatory conditions. Its primary product, Ryoncil (remestemcel-L), is an FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is advancing rexlemestrocel-L for chronic low back pain associated with degenerative disc disease and heart failure, and is evaluating Ryoncil for Duchenne muscular dystrophy and adult graft-versus-host disease. Mesoblast utilizes a proprietary technology platform to expand mesenchymal lineage cells from healthy adult donors for scalable manufacturing. It maintains commercial partnerships in Japan, Europe, and China, and operates locations in Australia, the United States, and Singapore. The company was incorporated in 2004 and is dual-listed on the Australian Securities Exchange and Nasdaq.

Summarised from the company's own disclosures, fiscal year ended Aug 2026

Industry Biotechnology Homepage mesoblast.com
Sector Healthcare IR page investorsmedia.mesoblast.com
Tags
allogeneic cell therapy, mesenchymal stromal cells, graft-versus-host disease, chronic low back pain, heart failure, duchenne muscular dystrophy, inflammatory bowel disease, cellular medicine, bioreactor technology, pediatric oncology, Ryoncil, remestemcel-L, rexlemestrocel-L, Revascor, Mesoblast Inc.
Press page —

Metrics

Valuation  
Market cap $ 18.999B
Market cap (USD) $ 18.999B
P/E -33.00
PEG —
P/BV 33.43
P/S 158.00
P/OCF -433.47
P/FCF -425.39
Dividend yield —
Turnover / mcap —
Returns  
ROE -9.9%
ROI -8.4%
ROIC -8.4%
Profit margin -47.8%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) —
Debt/Equity 21.0%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 125
Quality score -35.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016
Revenue 120.25M 17.198M 5.902M 7.501M 10.214M 7.456M 32.156M 16.722M 17.341M 2.412M —
Net profit -57.5M -102.142M -87.956M -81.889M -91.347M -98.811M -77.94M -89.799M -35.29M -76.815M -4.127M
Free cash flow -44.663M -50.634M -48.789M -63.583M -66.014M — — — — — -88.718M

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016
Share price 13.53 10.89 6.81 3.91 2.2 7.48 11.39 5.31 5.5 7.97 3.97
Price performance 12m 0.24 0.6 0.74 0.78 -0.71 -0.34 1.14 -0.03 -0.31 1.01 -0.73

Filed figures

Figure Jun 2017 Jun 2018 Jun 2019 Jun 2020 Jun 2021 Jun 2022 Jun 2023 Jun 2024 Jun 2025 Jun 2026
Balance sheet detail
Borrowings, current (USD) — — — — 53.2M 5.02M — — — —
Cash and deposits (USD) 45.8M — — — — — — — — —
Intangible assets (USD) 586M — — — — — — — — —
Cash flow detail
Purchases of property, plant and equipment (USD) -311,000 — — — — — — — — —
Income taxes paid (cash effect) (USD) 1,000 — — — — — — — — —
Income detail
Research and development expense (USD) 58.9M 65.9M 59.8M 56.2M 53M 32.8M 27.2M 25.4M 34.8M 97.5M
↳ 5y CAGR -2.2% +1.2% -11.0% -16.2% -15.8% -9.1% +13.0%
Reported Aug 30, 2017 Aug 31, 2018 Sep 9, 2019 Sep 3, 2020 Aug 31, 2022 Aug 31, 2022 Aug 31, 2023 Aug 29, 2024 Aug 29, 2025 Aug 27, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

2 This presentation includes forward-looking statements and forecasts that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward- looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this presentation are forward-looking statements. Words such as, but not limited to, “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “targets,” “likely,” “will,” “would,” “could,” and similar expressions or phrases identify forward-looking statements.

Mesoblast Limited — Announcement (Form 6-K) Bull 0 Bear 0 Routine

MESOBLAST SHOWCASED AT ASX PREMIER INVESTOR DAY EVENT New York, USA: November 15 and Melbourne, Australia: November 16, 2026: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it was highlighted at the Australian Securities Exchange (ASX) Investor Day in Melbourne at the session titled “Meet the CEO: Inside Australia’s Listed Companies.” The presentation highlighted Mesoblast’s transformation into a commercial-stage biotechnology company, continued growth of Ryoncil® (remestemcel-L-rknd) and the opportunity to leverage the Company’s cellular therapy platform across multiple high-value indications. Mesoblast also outlined its key value-creation priorities, including expansion of RYONCIL into adult acute graft-versus-host disease, advancement of rexlemestrocel-L for inflammatory chronic low back pain and cardiopulmonary indications of end-stage heart failure and pulmonary hypertension related to left ventricular function, and disciplined deployment of capital to support commercial growth and late-stage development programs.

Mesoblast Limited — Announcement (Form 6-K) Bull 0 Bear 0 Routine

Appendix 3X Initial Director’s Interest Notice + See chapter 19 for defined terms. 11/3/2002 Appendix 3X Page 1 Rule 3.19A.1 Appendix 3X Initial Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Name of entity MESOBLAST LIMITED ABN 68 109 431 870 We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Jon Voigtman Date of appointment 10 November 2026 Part 1 - Director’s relevant interests in securities of which the director is the registered holder In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Number & class of securities Not applicable. Exhibit 99.1

Appendix 3X Initial Director’s Interest Notice + See chapter 19 for defined terms.

Prompts

Mesoblast Limited (ticker MESO), listed in United States.

Company History

Date Change Detail
Jun 30, 2014 Reporting currency Its AU reports are in USD instead of AUD from this period. Earlier figures are shown in USD, converted at each period end's exchange rate.

ETFs Holding Mesoblast Limited

ETF Weight in ETF Shares Market value As of
AVDS 0.04% 107,941 $ 134.919K Nov 16, 2026
DFIS 0.03% 1,245,253 $ 1.658M Nov 12, 2026
APIE 0.01% 8,838 $ 148.125K Aug 31, 2026
DFIC 0.01% 777,980 $ 1.036M Nov 12, 2026
DFAX 0.00% 378,277 $ 503.621K Nov 12, 2026
DFSI 0.00% 35,588 $ 47.38K Nov 12, 2026
DFAI 0.00% 399,292 $ 531.599K Nov 12, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
MESO canonical Common share — US nasdaq 14.65 USD 2026-09-30
MSB Common share — AU asx 12,609.95 AUD 2026-01-09